Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease

18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer’s disease (AD) patients at the mild cognitive impairment (MCI) stage

(2017) Silvia Morbelli et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline

(2017) Nare Torosyan et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Why has therapy development for dementia failed in the last two decades?

(2016) Serge Gauthier et al.   Alzheimers & Dementia

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

(2016) Bruno Dubois et al.   Alzheimers & Dementia

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer’s disease

(2016) T A Pascoal et al.   MOLECULAR PSYCHIATRY

VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis

(2016) Sulantha Mathotaarachchi et al.   Frontiers in Neuroinformatics

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation

(2015) Sylvia Villeneuve et al.   BRAIN

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Association of hypometabolism and amyloid levels in aging, normal subjects

(2014) V. J. Lowe et al.   NEUROLOGY

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

(2014) Reisa Sperling et al.   NEURON

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment

(2013) A. Brück et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

(2012) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

(2012) A. D. Joshi et al.   JOURNAL OF NUCLEAR MEDICINE

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative

(2012) Joshua D. Grill et al.   NEUROBIOLOGY OF AGING

Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials

(2012) Dominic Holland et al.   PLoS One

Tau pathology in children and young adults: can you still be unconditionally baptist?

(2011) Charles Duyckaerts   ACTA NEUROPATHOLOGICA

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

BEaST: Brain extraction based on nonlocal segmentation technique

(2011) Simon F. Eskildsen et al.   NEUROIMAGE

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease

(2009) Marine Fouquet et al.   BRAIN

Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection

(2009) Kelvin K. Leung et al.   NEUROIMAGE

Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease

(2008) L. Mosconi et al.   NEUROLOGY